102 chapter 2 Table 3. Baseline characteristics of included studies investigating BRAF point mutations reference country study design ntot ni included indeterminate cytology Xing 2004 USA PS 48 25 indeterminate Sapio 2007 (1) Italy PS 144 47 microfollicular pattern with or without Hürthle cells, scant colloid, no nuclear atypia Sapio 2007 (2) Italy n.s. 132 21 indeterminate Kim 2008 South Korea RS 103 27 (suspicious for) follicular neoplasm and/or atypia Jo 2009 South Korea PS 101 20 indeterminate Marchetti 2009 Italy RS 111 20 indeterminate Cantara 2010 Italy PS 235 41 indeterminate Moses 2010 USA PS 455 110 follicular or Hürthle cell neoplasm Adeniran 2011 (1) USA RS 84 84 Bethesda III Adeniran 2011 (2) USA PS 157 89 Bethesda III FLUS Kim 2011 South Korea PS 865 151 Bethesda III AUS Nikiforov 2011 USA PS 1,056 461 Bethesda III or IV Patel 2011 Ukraine RS 134 20 Bethesda IV Pelizzo 2011 Italy PS 270 119 Thy3 Yeo 2011 South Korea n.s. 973 60 Bethesda III FLUS or follicular neoplasm Canadas-Garre 2012 Spain PS 1,031 57 indeterminate Kang 2012 South Korea n.s. 1,060 21 Bethesda III or IV Mancini 2012 Italy n.s. 260 48 Thy3 Rossi 2012 Italy PS 2,421 200 Bethesda III or IV Tonacchera 2012 Italy PS 153 54 indeterminate Carr 2013 USA RS 140 42 Bethesda III Jeong 2013 South Korea RS 165 103 Bethesda III Kloos 2013 USA PS 296 165 Bethesda III or IV Koh 2013 South Korea RS 518 27 Bethesda III or IV Ohori 2013 USA RS 483 424 Bethesda IV, excluding SHCN/HCN Agretti 2014 Italy n.s. 153 54 Bethesda III FLUS Beaudenon-Huibregtse 2014 USA PS 806 80 Bethesda III or IV Danilovic 2014 Brazil PS 202 136 Bethesda III or IV Eszlinger 2014 (1) Denmark RS 310 164 indeterminate
RkJQdWJsaXNoZXIy MTk4NDMw